Bajaj Finserv Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended)
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹11.07-0.97%
23 Oct 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for Bajaj Finserv Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (31.7%)
Mid Cap (30.1%)
Small Cap (38.1%)
Historical Asset Allocation
| Asset | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Equity | 95.56% | 95.97% | 96.58% | 96.15% | 95.80% | 96.71% |
| Debt | 3.66% | 3.46% | 2.55% | 2.96% | 3.06% | 3.25% |
| Others (incl. cash) | 0.78% | 0.57% | 0.87% | 0.89% | 1.14% | 0.04% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
35
P/E Ratio
48.71
P/B Ratio
5.93
Top Holding %
9.75%
Top 5 Holdings %
37.18%
Top 10 Holdings %
59.23%
AUM
₹405 Cr
Expense Ratio
0.90%
Since Inception
5.73%
Max Drawdown
-0.16%
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | Healthcare | 42,533 | 39.52 | 9.75% | -0.80%↓ |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 1,99,824 | 36.3 | 8.96% | 0.75%↑ |
| Piramal Pharma Ltd. | Healthcare | 12,46,805 | 25.75 | 6.36% | -0.36%↓ |
| Rubicon Research Ltd. | Healthcare | 1,51,995 | 24.61 | 6.08% | -0.73%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 1,46,132 | 24.43 | 6.03% | -0.15%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 27,355 | 22.34 | 5.51% | -0.49%↓ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 40,333 | 19.36 | 4.78% | -0.25%↓ |
| Emcure Pharmaceuticals Ltd. | Healthcare | 84,054 | 16.33 | 4.03% | 0.19%↑ |
| Laurus Labs Ltd. | Healthcare | 80,000 | 15.84 | 3.91% | 1.55%↑ |
| Neuland Laboratories Ltd. | Healthcare | 7,242 | 15.46 | 3.82% | -0.29%↓ |
| Max Healthcare Institute Ltd. | Healthcare | 1,30,366 | 12.12 | 2.99% | -0.36%↓ |
| Alkem Laboratories Ltd. | Healthcare | 23,236 | 12 | 2.96% | - |
| Zydus Lifesciences Ltd. | Healthcare | 89,621 | 10.41 | 2.57% | 0.01%↑ |
| Ipca Laboratories Ltd. | Healthcare | 50,483 | 9.73 | 2.40% | -0.06%↓ |
| Fortis Healthcare Ltd. | Healthcare | 1,20,183 | 9.25 | 2.28% | -0.41%↓ |
| Zydus Wellness Ltd. | Consumer Staples | 1,73,510 | 8.9 | 2.20% | -0.07%↓ |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 61,718 | 8.87 | 2.19% | -0.12%↓ |
| Senores Pharmaceuticals Ltd. | Healthcare | 60,946 | 8.45 | 2.08% | -0.07%↓ |
| Shaily Engineering Plastics Ltd. | Materials | 24,809 | 7.6 | 1.88% | -0.12%↓ |
| Dr. Lal Pathlabs Ltd. | Healthcare | 35,236 | 7 | 1.73% | 0.05%↑ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 89.35% | 88.25% | 87.60% | 86.77% | 86.16% | 86.32% |
| Consumer Staples | 2.20% | 2.27% | 2.66% | 2.82% | 2.65% | 5.27% |
| Materials | 1.88% | 2.00% | 2.02% | 2.03% | 2.23% | 1.94% |
| Chemicals | 1.38% | 1.45% | 2.28% | 2.17% | 2.14% | 2.11% |
| Services | 0.75% | 0.82% | 0.96% | 1.04% | 1.12% | 1.07% |
| Financial | - | 0.92% | 0.83% | 1.00% | - | - |
| Capital Goods | - | 0.26% | 0.23% | 0.32% | 0.59% | - |
| Insurance | - | - | - | - | 0.91% | - |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
28.2 / 100
Weighted average Value score is 28.2. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
70.1 / 100
Weighted average Price Momentum score is 70.1. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
82.9 / 100
Weighted average Quality score is 82.9. This indicates that portfolio has high quality using composite of quality measures.
QVM score
68.9 / 100
Weighted average QVM score is 68.9. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of Bajaj Finserv Healthcare Fund Direct-Growth?
The top holdings of Bajaj Finserv Healthcare Fund Direct-Growth as of 30 Sep 2026 are Divis Laboratories Ltd. (9.75%), Sun Pharmaceutical Industries Ltd. (8.96%), Piramal Pharma Ltd. (6.36%), Rubicon Research Ltd. (6.08%), Aurobindo Pharma Ltd. (6.03%). These top 5 stocks together account for 37.18% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does Bajaj Finserv Healthcare Fund Direct-Growth hold in its portfolio?
Bajaj Finserv Healthcare Fund Direct-Growth holds 35 stocks in its portfolio as of 30 Sep 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of Bajaj Finserv Healthcare Fund Direct-Growth?
As of 30 Sep 2026, Bajaj Finserv Healthcare Fund Direct-Growth's top sector allocations are Healthcare (89.35%), Consumer Staples (2.20%), Materials (1.88%). You can find detailed sector allocation above.
What is the equity and debt allocation of Bajaj Finserv Healthcare Fund Direct-Growth?
As of 30 Sep 2026, Bajaj Finserv Healthcare Fund Direct-Growth has 95.56% allocated to equity, and 3.66% to debt. You can also check the historical trends above.
What is the market cap allocation of Bajaj Finserv Healthcare Fund Direct-Growth?
As of 30 Sep 2026, Bajaj Finserv Healthcare Fund Direct-Growth's market cap allocation is 31.74% in large caps, 30.13% in mid caps, and 38.13% in small caps.
What is the PE ratio of Bajaj Finserv Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of Bajaj Finserv Healthcare Fund Direct-Growth is 48.71 as of 30 Sep 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of Bajaj Finserv Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for Bajaj Finserv Healthcare Fund Direct-Growth — its non-equity allocation was 3.66% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for Bajaj Finserv Healthcare Fund Direct-Growth?
The latest portfolio disclosure for Bajaj Finserv Healthcare Fund Direct-Growth is as of 30 Sep 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.